The Nottingham facility acquired from Catalent [Image courtesy of Codis]
The Haverhill, England-based company agreed to acquire the oral solid dose (OSD) development and manufacturing plant in Nottingham last month. The facility adds OSD development and small-scale manufacturing capabilities to Codis’ offerings, enabling it to offer a single partner path for integrated spray-dry solutions. It can now provide development through clinical supply and commercial intermediates to final oral dose forms.
Codis, a global contract development and manufacturing organization (CDMO) specializing in spray drying, amorphous solid dispersions (ASDs), says its acquisition strategically complements its commercial spray drying facility in Haverhill. The company currently has work underway on an expansion for that facility, set for validation in 2027.
The combined capabilities enhance Codis’ portfolio of bioavailability enhancement solutions, the company said. It also provides customers with a seamless route from early development through clinical supply and commercial intermediates to final oral dose forms.
Commentary from Codis officials
Matthew Streeter, GM of the Nottingham site, who now joins the Codis executive team, said:
“My team and I are excited to join Codis and look forward to playing a big part in building an expanded, strategically important service at the company.”
Nicolas Fortin, Codis CEO, said:
“This is an exciting milestone for Codis. We are delighted to welcome the Nottingham team into the Codis family. Their scientific strength, development experience, and long track record of delivering high‑quality spray‑dried and oral solid dose solutions make them an exceptional addition to our organization. Together, Nottingham and Haverhill create a uniquely integrated pathway that allows customers to move from development to commercial manufacturing with greater speed, confidence, and continuity.”
Steve Facer, SVP of sales & marketing at Codis, said:
“This combination gives the market something truly differentiated. Codis now offers the most compelling spray dry offering in Europe with development expertise, integrated analytical support, clinical and small‑scale commercial manufacturing, and commercial‑scale spray drying all within one organization and one quality system. For customers working with poorly soluble molecules, this is the fastest and lowest‑risk path to unlocking a molecule’s full potential.”
Tell Us What You Think!